BFM
INDP icon

Boothbay Fund Management’s Indaptus Therapeutics INDP Stock Holding History

Boothbay Fund Management’s Portfolio INDP Stock Details INDP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-1
Closed -$922K – 831
2019
Q2 		$922K Buy
+1
New +$12.6K 0.08% 276

Other funds holding INDP

MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Boothbay Fund Management's INDP Position: Q4 2019 in Review

Boothbay Fund Management sold out of Indaptus Therapeutics (INDP) in Q4 2019, closing a stake of 29 shares — an estimated $48K sold.

Boothbay Fund Management first reported a position in INDP in Q2 2018 and held it in 6 quarters. The position peaked at $555K in Q4 2018. 25 funds tracked by Wall St. Rank hold INDP as of Q4 2019.

  • Boothbay Fund Management reported no remaining Indaptus Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Boothbay Fund Management sold 29 Indaptus Therapeutics shares in Q4 2019, an estimated $48K.
  • Boothbay Fund Management first reported a position in Indaptus Therapeutics in Q2 2018 and held it in 6 quarters.
  • Boothbay Fund Management's Indaptus Therapeutics position peaked at $555K in Q4 2018.
  • 25 funds tracked by Wall St. Rank held Indaptus Therapeutics as of Q4 2019.

Based on Boothbay Fund Management's 13F filing for Q4 2019, filed 14 Feb 2020.